Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (221-230 of 251) with videos related to

Pageof 26
Sort By:
Haematologica|February 25, 2021
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemiaVincent Jachiet, Guillaume Moulis, Jérome Hadjadj, et al.
Blood Advances|April 12, 2022
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trialMarina Y Konopleva, Christoph Röllig, Jamie Cavenagh, et al.
Blood|February 21, 2012
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromesFrederik Damm, Olivier Kosmider, Véronique Gelsi-Boyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
American Journal of Hematology|December 31, 2013
Azacitidine in untreated acute myeloid leukemia: a report on 149 patientsSylvain Thépot, Raphael Itzykson, Valerie Seegers, et al.
Haematologica|February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
British Journal of Haematology|April 19, 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutationsLionel Adès, Nicolas Duployez, Agnes Guerci-Bresler, et al.
Blood|September 20, 2013
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disordersFrederik Damm, Virginie Chesnais, Yasunobu Nagata, et al.
Pageof 26

Showing results (221-230 of 251) with videos related to

Sort By:
Pageof 26
Haematologica|February 25, 2021
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemiaVincent Jachiet, Guillaume Moulis, Jérome Hadjadj, et al.
Blood Advances|April 12, 2022
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trialMarina Y Konopleva, Christoph Röllig, Jamie Cavenagh, et al.
Blood|February 21, 2012
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromesFrederik Damm, Olivier Kosmider, Véronique Gelsi-Boyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
American Journal of Hematology|December 31, 2013
Azacitidine in untreated acute myeloid leukemia: a report on 149 patientsSylvain Thépot, Raphael Itzykson, Valerie Seegers, et al.
Haematologica|February 6, 2025
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)Sarah Bertoli, Emilie Bérard, Pierre Peterlin, et al.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
British Journal of Haematology|April 19, 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutationsLionel Adès, Nicolas Duployez, Agnes Guerci-Bresler, et al.
Blood|September 20, 2013
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disordersFrederik Damm, Virginie Chesnais, Yasunobu Nagata, et al.
Pageof 26